Pawar Anil, Pal Amit, Goswami Kalyan, Squitti Rosanna, Rongiolettie Mauro
Department of Zoology, DAV University, Jalandhar 144012, Punjab, India.
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Kalyani 741245, West Bengal, India.
Results Chem. 2021 Jan;3:100148. doi: 10.1016/j.rechem.2021.100148. Epub 2021 Jun 12.
The world's largest randomized control trial against COVID-19 using remdesivir, hydroxychloroquine, lopinavir and interferon-β1a appeared to have little or no effect on hospitalized COVID-19 patients. This has again led to search for alternate re-purposed drugs and/or effective "add-on" nutritional supplementation, which can complement or enhance the therapeutic effect of re-purposed drug. Focus has been shifted to therapeutic targets of severe acute respiratory syndrome coronavirus (SARS-CoV-2), which includes specific enzymes and regulators of lipid metabolism. Very recently, fenofibrate (cholesterol-lowering drug), suppressed the SARS-CoV-2 replication and pathogenesis by affecting the pathways of lipid metabolism in lung cells of COVID-19 patients. A preclinical study has shown synergistic effect of quercetin (a flavonoid) and fenofibrate in reducing the cholesterol content, which might be useful in COVID-19 treatment. Based on the scientific literature, use of quercetin and fenofibrate in COVID-19 seems meaningful in pharmaceutical and biomedical research, and warrants basic, experimental and clinical studies. In this article, we have summarized the contemporary findings about drug fenofibrate and its effect on membrane synthesis of COVID-19 virus along with emphasizing on possible synergistic effects of quercetin with fenofibrate.
全球最大规模的针对新冠病毒使用瑞德西韦、羟氯喹、洛匹那韦和干扰素-β1a的随机对照试验，似乎对住院的新冠患者几乎没有效果。这再次促使人们寻找其他重新利用的药物和/或有效的“附加”营养补充剂，它们可以补充或增强重新利用药物的治疗效果。研究重点已转向严重急性呼吸综合征冠状病毒（SARS-CoV-2）的治疗靶点，其中包括脂质代谢的特定酶和调节剂。最近，非诺贝特（一种降胆固醇药物）通过影响新冠患者肺细胞中的脂质代谢途径，抑制了SARS-CoV-2的复制和发病机制。一项临床前研究表明，槲皮素（一种类黄酮）和非诺贝特在降低胆固醇含量方面具有协同作用，这可能对新冠治疗有用。基于科学文献，在新冠治疗中使用槲皮素和非诺贝特在药物和生物医学研究中似乎具有意义，值得进行基础、实验和临床研究。在本文中，我们总结了关于非诺贝特药物及其对新冠病毒膜合成影响的当代研究结果，并强调了槲皮素与非诺贝特可能的协同作用。
